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Insulin resistanceThere is increasing evidence showing that inﬂammation is an important pathogenic mediator of the development
of obesity-induced insulin resistance. It is now generally accepted that tissue-resident immune cells play a major
role in the regulation of this obesity-induced inﬂammation. The roles that adipose tissue (AT)-resident immune
cells play havebeen particularly extensively studied. AT containsmost types of immune cells and obesity increases
their numbers and activation levels, particularly in AT macrophages (ATMs). Other pro-inﬂammatory cells found
in AT include neutrophils, Th1 CD4 T cells, CD8 T cells, B cells, DCs, and mast cells. However, AT also contains
anti-inﬂammatory cells that counter the pro-inﬂammatory immune cells that are responsible for the
obesity-induced inﬂammation in this tissue. These anti-inﬂammatory cells include regulatory CD4 T cells
(Tregs), Th2 CD4 T cells, and eosinophils. Hence, AT inﬂammation is shaped by the regulation of pro- and
anti-inﬂammatory immune cell homeostasis, and obesity skews this balance towards a more pro-inﬂammatory
status. Recent genetic studies revealed several molecules that participate in the development of obesity-induced
inﬂammation and insulin resistance. In this review, the cellular and molecular players that participate in the reg-
ulation of obesity-induced inﬂammation and insulin resistance are discussed, with particular attention being
placed on the roles of the cellular players in these pathogeneses. This article is part of a Special Issue entitled:
Modulation of Adipose Tissue in Health and Disease.
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Insulin resistance is the condition where the body does not
respond appropriately to circulating insulin [1,2]. It associates com-
monly with obesity, hypertension, and cardiovascular disease and
typically precedes the onset of Type 2 Diabetes (T2D). Insulin resis-
tance occurs in several tissues, including the liver, muscle and adipose
tissue (AT). The liver helps to maintain fasting glucose levels through
gluconeogenesis and glycogenolysis. However, when the liver is
insulin-resistant, the suppression of hepatic glucose production is
impaired and thus gluconeogenesis and glycogenolysis continue at
inappropriately high levels despite normal or high circulating glucose
levels. AT and muscle are similarly affected by insulin resistance,
although the problem here relates more to the impaired ability of
insulin to promote glucose disposal. To compensate for the insulin
resistance in these tissues, pancreatic β-cells produce more insulin.
However, there is a limit to how much can be produced, and when
this has been reached, the β-cells fail. T2D occurs when an inappro-
priately low level of insulin is produced in response to a given
concentration of glucose.
At the cellular level, the molecular mechanism that underlies the
development of insulin resistance is impairment in the insulin signal-
ing pathway in insulin-responsive cells (adipocytes, myocytes, hepa-
tocytes and β-cells). Normally, when insulin binds to the insulin
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at its Tyr residues and its tyrosine kinase is activated [3,4]. The
insulin receptor then phosphorylates tyrosine residues on the insulin
receptor substrates (IRSs), which then serve as docking proteins
for SH2-containing enzymes such as p85 subunit of PI-3 kinase or
SHP2. This leads to linear signaling cascades that result in Akt activa-
tion. The activation of Akt induces the translocation of Glut4 and
glycogen synthesis and thus plays an important role in metabolic
signaling. Hence, disruption of this insulin signaling cascade can
induce insulin resistance and is associated with the development of
T2D. It is widely agreed in the ﬁeld that obesity is a major cause of
impaired insulin signaling and therefore the development of insulin
resistance. However, it is not fully understood how obesity causes
the development of insulin resistance. Many molecular mechanisms
are proposed, including ER stress, oxidative stress, dysregulation of
lipid homeostasis (including FFA homeostasis), mitochondrial dys-
function, hypoxia and others [5]. However, there are now many
lines of evidence that suggest that obesity-induced inﬂammation
may also be a key cause of insulin resistance. Recent studies in this
ﬁeld have also identiﬁed many cellular and molecular players that
participate in the development of obesity-induced inﬂammation and
insulin resistance.
2. Obesity-induced Inﬂammation
Inﬂammation is a series of cellular and molecular responses that
serve to defend the body from infections or other insults. These
responses also help the tissues that were damaged by the insults
(and the immune responses that were induced by the insults) to
recover. Inﬂammation has mainly been studied in infectious models
but its dysregulation has also been implicated as a major cause of
many diseases such as rheumatoid arthritis, atherosclerosis, asthma
and other autoimmune diseases [6–8]. The main cellular players in
inﬂammation are immune cells, which can be roughly divided into
pro- and anti-inﬂammatory immune cells whose relative balance
and functions tightly control the inﬂammation processes [9]. For
example, when cells are infected by foreign bacteria or viruses, the
danger signals produced by these infected cells are detected by
surveilling immune cells, particularly neutrophils. The neutrophils
then migrate into the local sites of infection, where they produce a
series of chemokines that recruit other immune cells. Macrophages
are recruited ﬁrst, after which lymphocytes are recruited. The inﬁl-
trating immune cells then kill and remove the infected cells, after
which the inﬂammation resolves and tissue healing starts. Finally, B
cells mediate the transition from innate immunity to adaptive immu-
nity. When inﬂammation is induced without infection, it is called
sterile inﬂammation. In this case, the cells are mainly killed by necro-
sis and produce DAMPs such as HMGB1 and dsDNA that bind to PRRs
such as TLRs, thereby initiating inﬂammation. Thus, in general, in-
ﬂammation is often characterized by increased cytokine levels in
the circulation and local sites of inﬂammation along with increases
in the inﬁltrating immune cell numbers in the local sites. Acute
inﬂammation is often deﬁned as the presence of neutrophils at the
sites of inﬂammation while chronic inﬂammation is generally deﬁned
as the inﬁltration of macrophages into the inﬂamed tissue.
While obesity-induced inﬂammation resembles the inﬂammation in
classical immunity in manyways, it also differs from the latter in that it
is a low-grade inﬂammation that produces much lower levels of circu-
lating cytokines. It is also considered to be a chronic inﬂammation
because it requires relatively long diet treatments (>8 weeks in animal
models) before it becomes clearly discernible in the AT, which of all the
various insulin-responsive tissues has the most severe obesity-induced
inﬂammation (as characterized by the increased cytokine/chemokine
expression and immune cell inﬁltration). Indeed, obesity-induced in-
ﬂammation particularly resembles the inﬂammation observed in ath-
erosclerosis, which is one of the complications of metabolic syndromealong with insulin resistance and lipid dysregulation [10]. Thus, obesity-
induced inﬂammation may be a different kind of inﬂammation, namely
one that is the result of overnutrition and stress pathways that drive
abnormal metabolic homeostasis (e.g., high levels of lipid, FFA, glucose
or ROS).
The role of inﬂammation in the development of obesity-induced
insulin resistance was ﬁrst suggested by the early studies on TNFα
in the 1990s. These studies showed that when adipocytes were treat-
ed with TNFα, their insulin signaling was impaired, mainly because of
changes in the transcription of insulin signaling molecules, in partic-
ular the insulin receptor, IRS-1, and Glut4 [11,12]. Animal studies
also revealed that interventions that increased TNFα levels induced
insulin resistance, and that the blocking of TNFα functions by genetic
and pharmacological interventions improved obesity-induced insulin
resistance [13–17]. Thus, these were the ﬁrst studies to show that an
inﬂammatory mechanism, namely the pro-inﬂammatory cytokine
TNFα, can regulate obesity-induced insulin resistance in vitro and in
vivo. While most of these studies focused on TNFα rather than on
inﬂammation per se, they provided the novel concept that an immune
pathway may regulate the development of obesity-induced insulin
resistance.
Then, in the early 2000s, a series of epidemiological studies
revealed that circulating inﬂammatory markers associate strongly
with T2D and are risk factors for the development of future T2D
[18–29]. These clinical but still observational studies were then
supported by preclinical studies showing that obesity activates
inﬂammation via the IKKβ/NFκB pathway and that inhibition of this
pathway by genetic deletion of IKKβ or pharmacological inhibitors
of this pathway (a high dose of salicylates or aspirin) improves
obesity-induced insulin resistance [30,31]. Clinical studies then showed
that when inﬂammation in insulin-resistant or T2D patients was
suppressed by a high dose of aspirin or salsalate (a dimer of salicylate),
the glycemic control of the patients improved, along with concomitant
inhibition of NFκB activity in their PBMCs [32–35]. Numerous pre-
clinical and clinical studies now strongly support the notion that
obesity-induced inﬂammation plays an important role in the devel-
opment of insulin resistance and T2D [36,37].
The next question was, “Which tissues/cells mediate the regula-
tion of obesity-induced inﬂammation?” Two seminal papers by the
Chen and Ferrante groups tested this question directly [38,39]. They
showed that obesity increases AT macrophage (ATM) numbers and
that ATMs, not adipocytes, produce the majority of cytokines in re-
sponse to obesity. This made it clear that AT-inﬁltrated macrophages
play a key role in the regulation of obesity-induced inﬂammation.
Subsequently, many other types of immune cells were found in AT,
most of which participate in the development of obesity-induced
inﬂammation in AT as well. Hence, it is now generally accepted that
tissue-resident immune cells play a major role in the regulation of
obesity-induced inﬂammation and insulin resistance, like they do in
classical immunity inﬂammation [40]. This notion is also strongly
supported by studies examining the effects of genetic modulation of
speciﬁc inﬂammatory mediators in immune cells [5,41,42].
3. Cellular players in obesity-induced AT inﬂammation
Obesity is deﬁned as the expansion of fat, and obesity, especially in
abdominal fat depots, is a risk factor for the induction of metabolic
diseases. Therefore, to understand the molecular mechanisms that
underlie the development of obesity-induced insulin resistance, the
biology of AT has been studied extensively. In terms of glucose
homeostasis, liver, AT and muscle are the major players; while liver
maintains glucose levels between meals by producing glucose via
glycogenolysis and gluconeogenesis, AT and muscle take up glucose
after a meal. However, the AT only takes up a relatively small propor-
tion of the glucose after a meal, although the insulin signaling
and insulin-sensitive Glut4 regulation in AT have been studied
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via its glucose uptake ability. Instead, AT may regulate glucose ho-
meostasis indirectly by regulating lipid homeostasis [43]. AT is the
main site of lipid storage and many studies show that the modulation
of the lipid pathways in AT can regulate systemic lipid homeostasis. In
many cases, these modulations are accompanied by disruption of sys-
temic glucose homeostasis. One extreme case of this is lipodystrophy,
which is characterized by a near complete loss of fat that causes
signiﬁcant hyperlipidemia and induces insulin resistance [44]. When
the fat is restored with transplantation, the metabolic dysregulation
is completely reversed.
Another important function of AT in obesity is to act as an endocrine
organ that regulates the production of various hormones and cytokines
[45]. The hormones and cytokines that are produced by AT include lep-
tin, adiponectin, resistin, and cytokines such as TNF-α and IL-6. Obesity
regulates the production of these hormones/cytokines byAT. Indeed, AT
expresses very high levels of many inﬂammatory mediators in obesity
and is therefore considered to be themain inﬂammatory organ thatme-
diates obesity-induced inﬂammation. While AT is composed of many
different cell types, including adipocytes, pre-adipocytes (adipocyte
progenitors), endothelial cells, and immune cells, recent studies show
clearly that the regulation of inﬂammatory mediators is mainly
mediated by the stromal vascular cell (SVC) fraction that contains the
immune cells. Hence, adipokines can be divided into two groups:
“true adipokines” that are produced by adipocytes (e.g., leptin,
adiponectin, and most resistins), and “pseudo-adipokines” that are
produced by non-adipocytes (most inﬂammatory mediators, including
TNF-α and IL-10).
Several studies show that obesity changes the number and
functions of the various types of immune cells in the AT SVC fraction.
However, these studies should be examined closely for the way cell
numbers and functions are expressed, especially when immune cell
numbers are determined by ﬂow cytometric analyses. The current
literature uses three ways to present obesity-induced changes in
immune cell numbers. In the ﬁrst way, immune cell numbers are
expressed as percentages of total SVCs or AT immune cells. However,
ATMs are the main component of AT immune cells (40–60% of all AT
immune cells) and obesity dramatically increases ATM numbers.
Therefore, when immune cell numbers are normalized according to
total SVCs or AT immune cells, they can appear to be decreased by
obesity, even though their absolute numbers are increased. The
second way of expressing immune cell numbers is as total numberTable 1
Cellular players that participate in the development of obesity-induced AT inﬂammation an
Cells Targeting method: gene or mice Insulin resistance B
Dendritic cells T KO:Flt3 ↓ ↓
BMT(H):CD11c-DTR ↓ ↔
Neutrophils T KO:Elastase ↓ ↓
Eosinophils T KO:ΔdblGATA ↑ ↑
T KO: IL-4/IL-13 ND N
Mast celsl T KO:Kit W-sh/W-sh ↓ ↓
Th2 CD4 T cells T KO:Rag-1 ↑ ↑
CD4 Tregs Tg:Fxop3-DTR ↑ ↔
CD8 T cells T KO:CD8a ↓ ↔
NKT cells T KO:CD1d ↑ ↑
T KO:CD1d ↓ ↓
T KO:CD1d ↔ ↔
T KO:CD1d ↔ ↔
T KO:Jα18 ↑ ↑
T KO:Jα18 ↓ ↔
T KO:Jα18 ↔ ↔
T KO:β2 microglobulin ↓ ↔
B cells KO T:μMT ↓ ↔
KO T:μMT ↓ ↔
T KO, Total body knockout mice; BMT(H), Deletion of target genes in the hematopoietic com
wild type controls); ND, No determine.per fat pad. In this case, the changes in immune cell numbers are
compounded by the obesity-induced increase in the size of the fat.
As a result, if there is an actual increase in cell numbers, the changes
can appear to be very dramatic; by contrast, if the immune cell num-
bers actually decrease, this decrease may be minimal or indiscernible
when expressed in this fashion. In the third way, immune cell
numbers can be normalized by fat weight (i.e., they are expressed
as immune cell numbers per weight of fat) to compensate for the
obesity-induced increases in ATM numbers and fat sizes. Thus,
reports of obesity-induced changes in immune cell numbers should
be examined carefully, especially when rare cell populations are
being analyzed.
3.1. Myeloid cells
Leukocytes are grossly categorized as lymphocytes and myeloid
cells [46]. Myeloid cells include macrophages, DCs, mast cells, neutro-
phils, basophils and eosinophils, while lymphocytes include T, B, NK
and NKT cells. Although myeloid cells are believed to be key players
in innate immunity, they also play important roles in adaptive immu-
nity. For example, DCs are important for the antigen presentation that
is essential for the development of adaptive immunity. Furthermore,
many of the cytokines that are produced by myeloid cells help to
develop and activate T and B cells, which are also critical components
of adaptive immunity. The AT immune cell that was identiﬁed ﬁrst
was the AT macrophage (ATM), and it is presently the most well-
studied AT immune cell type. However, most of the other immune
cell types are also found in AT, and their roles in the development
of obesity-induced inﬂammation and insulin resistance have been
extensively investigated as well. Table 1 and Fig. 1 summarize the
roles of AT immune cells in the development of obesity-induced
inﬂammation and insulin resistance.
3.1.1. Macrophages
A key function of macrophages is to protect the body from infec-
tion by removing infected cells via phagocytosis and by killing
infected cells via cytokines [47]. While the phagocytosis function of
these cells is rarely considered in obesity-induced inﬂammation, it
could play a role as this is a key function in the wound repair and
tissue remodeling that occurs after the resolution of inﬂammation.
Macrophages also promote wound repair and tissue remodeling by
producing extracellular matrix (ECM) and proteinases to modifyd insulin resistance.
ody weight Adiposity ATM Reference
Number M1 M2
↓ ↓ ↓ ND [63]
↔ ↓ ↓ ND [62]
↑ ND ↓ ↑ [72]
↑ ↔ ND ↓ [76]
D ND ND ND ↓ [76]
↓ ↓ ND ND [79]
↑ ND ND ND [83]
↔ ND ND ND [87]
↔ ND ↓ ↔ [86]
↑ ↔ ↑ ND [91]
↓ ND ND ND [92]
↔ ↔ ND ND [94]
ND ND ND ND [96]
↑ ↑ ↑ ↓ [91]
↓ ↓ ND ND [92]
↔ ↔ ND ND [93]
↔ ↓ ND ND [97]
↓ ND ↓ ↑ [66]
↓ ↓ ↓ ↑ [67]
partment by bone marrow transplantation (Donor: T KO or transgenic mice, Recipients:
M2 ATMs
Neutrophils
M1 ATMs
Obesity
DCs
B Cells
Th1 CD4 Cells
CD8 T 
Cells
Mast 
Cells
Th2 CD4 
T CellsCD4 Tregs
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Adipocytes
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Angiogenesis
?
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Fig. 1. The roles of AT immune cells in the development of obesity-induced inﬂammation. This diagram is based on the current published ﬁndings that are discussed in this review.
The blue fonts represent cells that suppress inﬂammation, while the red fonts represent cells that induce inﬂammation. Since there are many contradictory reports regarding the
role of NKT cells, NKT cells are not categorized in this diagram.
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play important roles in the regulation of chronic inﬂammation,
mainly because of their strong capacity to produce cytokines. In
most chronic diseases, macrophages produce chemokines that recruit
other immune cells into the local inﬂammatory sites; they also pro-
duce pro-inﬂammatory cytokines that polarize and activate other
immune cells. However, in some cases, macrophages also exhibit
anti-inﬂammatory characteristics. An example of these macrophages
are the tumor-associated macrophages (TAMs) [48]. Hence, macro-
phages can play various roles in the initiation, progression and reso-
lution of inﬂammation.
Macrophages are typically deﬁned as CD11b+ and F4/80+ in ﬂow
cytometric analyses and do not express CD3, CD19 and NK1.1. Other
markers used to identify macrophages by ﬂow cytometry include
CD14, CD16 and CD68. In addition, macrophages are bigger and
more granular than lymphocytes and DCs and therefore do not
typically make a distinctive cluster in FSC (size)/SSC (granularity)
gating, unlike other immune cells. However, most of the macrophage
cell-surface markers are also expressed by many different cell types
(e.g., CD11b is also expressed by monocytes, granulocytes, NK cells,
T cells and B cells). Therefore, the best ﬂow cytometric results can
be often obtained by using negative selection (e.g., CD3, CD19 and
NK1.1 for macrophages) and positive selection (e.g., CD45, CD11b
and F4/80 for macrophages). Examples of gating strategies for the
ﬂow cytometric analyses of mouse AT and blood immune cells were
shown in Fig. 2. Also Tables 2 and 3 summarized the cell surface
markers that are commonly used for determining cell types by ﬂow
cytometric analyses.
Since macrophages are the key players in most cases of chronic
inﬂammation, it was a reasonable hypothesis that obesity-induced
inﬂammation is regulated by macrophages. Indeed, the Ferrante and
Chen groups showed that ATMs produce the majority of cytokines
(or “pseudoadipokines”) in obesity and that obesity increases ATM
numbers [38,39]. Subsequent studies in animals and humans con-
ﬁrmed that obesity increases ATM numbers [5,9,49]. They also
showed that loss of weight decreases ATM numbers and that
decreased ATM numbers often accompany improvements in insulin
resistance (such as that due to TZD treatment). Moreover, in mouse
models, overexpression of MCP-1 in AT increases ATM recruitment
and mildly exacerbates obesity-induced insulin resistance [50,51],
which supports the notion that ATMs regulate the development of
systemic insulin resistance in obesity.
Probably the most signiﬁcant but also immunologically unusual
feature of the obesity-induced changes in ATM is that obesitydramatically increases CD11c+ ATM numbers [52]. CD11c is consid-
ered to be a classical cell-surface marker of DCs, and thus DCs are gen-
erally deﬁned as CD11b- and CD11c+ while macrophages are deﬁned
as CD11b+ and CD11c− [53–55] (also see Fig. 2A). However, in obese
AT, the CD11c+ ATMs also express CD11b and F4/80 and are distinct
from the AT DCs, which express CD11c, but not CD11b (see
Section 3.1.2). Interestingly, obesity only appears to increase the
numbers of the triple-positive (CD11b+ F4/80+ CD11c+) ATM popu-
lation: the CD11b+ F4/80+ CD11c− ATM numbers remain unchanged
[56]. An in vivo labeling study then showed that the ATMs that reside
in the AT do not have CD11c whereas the ATMs that are newly
recruited by obesity express CD11c. Thus the obesity-induced
changes in ATM numbers are mainly due to increases in the triple-
positive CD11b+ F4/80+ CD11c+ ATM subpopulation. However, it is
not clear yet how obesity increases this special subpopulation. It is
possible that this population starts as a special subpopulation of
circulating monocytes that is recruited speciﬁcally into AT by obesity,
after which these cells differentiate into CD11c+ ATMs. It is also pos-
sible that the obese environment of AT locally induces the expression
of CD11c in newly-recruited CD11c− ATMs.
Macrophages are a very diverse group of cells: they are functionally
and morphologically different in different tissues, as indicated by the
alveolar macrophages in the lung, Kupffer cells in the liver, microglia
in the neural tissues, and osteoclasts in bone [47,57]. Furthermore,
even in the same tissue, there are many different subpopulations of
macrophages. The best-known example of this is the splenic macro-
phage population. A paper from the ImmGen consortium recently con-
ﬁrmed that different tissues share this vast macrophage subpopulation
diversity [54]. Despite this diversity, macrophages are often categorized
by the binary M1 and M2 system [57]. The M1 and M2 phenotypes are
deﬁned by the in vitro system: M1 macrophages are generated by
treating BMDMs with LPS and IFNγ or other pro-inﬂammatory cyto-
kines while M2 macrophages are generated by treating these cells
with IL-4/IL13 or IL-10. The resulting M1 macrophages are Th1-biased
and considered to be pro-inﬂammatorymacrophages andmost notably
express TNFα and IL-6.Most of themacrophages found in the sites of in-
ﬂammation in inﬂammatory diseases are considered to be M1 macro-
phages. By contrast, M2 macrophages are Th2-biased and are thought
to play more diverse roles, namely in anti-inﬂammatory pathways, tis-
sue remodeling and wound healing. Tumor-associated macrophages
(TAMs) are considered to be M2 macrophages.
Many studies have sought to categorize ATMs according to the
M1/M2 system and the general consensus in the ﬁeld at present is
that obesity induces the exclusive polarization of ATMs from M2
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Fig. 2. Examples of ﬂow cytometric analyses of mouse AT and circulating immune cells. A. Gating strategies for ATMs and AT DCs. After SVCs were isolated from AT by using a col-
lagenase method, they were stained with antibodies against cell-speciﬁc markers and subjected to ﬂow cytometric analysis with LSR II. The data were analyzed by FlowJo software
with the following gating strategy. Since ATMs have high granularity (SSC), we used the logistic scale for the SSC gating. After the appropriate cells were selected by FSC-A (size)/
SSC (granularity) gating (1), the aggregated cells were removed by FSC-A/FSC-W gating (2). The total leukocytes were then identiﬁed by positivity for CD45 (3). Thereafter, the
lymphocytes and RBCs were excluded by removing the CD3+ (T cells), CD19+ (B cells), NK1.1+ (NK and NKT cells) and TER119+ (RBC) cells (4). The AT DCs were selected as
CD11b− and CD11c+ (5). Finally, ATMs were determined by identifying the CD11b+ and F4/80+ cells (6). B. Gating strategies for circulating immune cells. Whole blood was incu-
bated with FcBlock to block the non-speciﬁc binding of Abs and then stained with antibodies against cell-speciﬁc surface markers. After staining, the RBCs were removed by lysing
with FACS Lysing buffer (BD Biosciences). The cells were then analyzed with LSR II. The data were analyzed by FlowJo software with the following gating strategy. After the appro-
priate cells were selected by FSC-A (size)/SSC (granularity) gating (1), the aggregated cells were removed by FSC-A/FSC-W gating (2). The total leukocytes were then selected by
positivity for CD45 (3). The neutrophils were selected as Gr-1+ and SSChi, while monocytes were selected as Gr-1+ and SSClo (4). It should be noted that this gating strategy selects
only the Ly6C+ (Gr-1+) monocyte subpopulation and that the total monocyte population containing both the Ly6C+ and Ly6C−monocyte subpopulations should be selected on the
basis of their CD11b and/or CD115 positivity. Thereafter, the lymphocyte population was selected as Gr-1- and SSClo (4). B cells were then selected as CD19+ from the lymphocyte
population (5). Finally, NK, NKT and T cells from the CD19- non-B cell population were further determined on the basis of their CD3 and/or NK1.1 expression levels (6). Cell surface
markers that were used to deﬁne speciﬁc cell types by these gating strategies were listed in the boxes. Potential negative selection markers that can be used together were also
listed with the parentheses at the end of positive selection markers. It should be also noted that the examples of the gating strategies shown here are only for the mouse immune
cell analyses and that they are only for the general guidance.
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marker, while CD206, CD209 and CD301 (Mgl1/2) are often used as
M2 ATM markers. However, ﬂow cytometry analyses show that
ATMs simultaneously express both CD11c and MGL1 (CD301) [56].
This suggests that individual ATMs can bear both M1 and M2 charac-
teristics simultaneously. Furthermore, M2 phenotypes, not M1 phe-
notypes, correlate with BMI in humans [58], and ATMs from obese
human express the genetic signature of TAMs [59]. This suggests
that obesity may induce the polarization of M2 macrophages, not
M1 macrophages. These contradictions could suggest that an ATM
subpopulation with a predominantly M1 phenotype coexists with an-
other ATM subpopulation that predominantly bears anM2 phenotypeand that it is the overall balance between these two ATM subpopula-
tions that shapes obesity-induced inﬂammation. It is also possible that
the M1/M2 system is just too simpliﬁed to adequately represent the
heterogeneity of ATMs in obesity, and thus may not be helpful for
understanding the role of these cells in obesity-induced inﬂammation.
Another notable feature of obese ATMs is that obese AT contains
unique clusters of macrophages that surround dead adipocytes.
These clusters are called crown-like structures (CLSs) and are mainly
observed in AT from obese animals and humans [60]. They also
express high levels of TNFα. However, since CLSs can be only deter-
mined by microscopical techniques and the CLS-speciﬁc surface
markers that can be used for ﬂow cytometric analyses have not yet
Table 2
Cell surface markers that can be used to determine mouse immune cell types by the ﬂow cytometric analysis.
Cell types Pan/commonly used
markers
Other pan markers Subset/activation markers Negative selection markers
T cells CD3, CD4 and/or CD8 CD25, CD69, CD44, CD62L, Foxop3 (intracellular) CD19, CD115, F4/80 NK1.1
B cells CD19 CD22, CD45R/B220, IgM CD25, CD69, CD86, CD279/PD-1 CD3, CD115, F4/80 NK1.1
NKT cells CD3, NK1.1 CD16, CD1d-α-gal-cer Tetramer CD19, CD115, F4/80
Macrophages CD11b, F4/80 CD14, CD16, CD64, CD68, CD115,
MerTK
CD11c for ATMs, CD206, CD209, CD301, MHC II CD3, CD19, Ly6G NK1.1
DCs CD11c, CD83 CD86, CD205/DEC-205, CD4, CD8, CD11b, CD45R/B220, CD80, CD103, CD209/
DC-Sign, MHC II
CD11b for AT DCs, CD3, CD19, Ly6G,
NK1.1
Neutrophils GR-1 or Ly6G Ly6B/7/4 CD11b, CD14, CD16, CD64 CD3, CD19, CD115, NK1.1
All of cells are typically gated ﬁrst with CD45+ (leukocytes) and TER119- (red blood cells) (see Fig. 2). It should be noted that markers in this table are only for the analyses of mouse
immune cells. It should be also noted that negative selection markers listed in this table are only for the general guidance.
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at present.
All published studies strongly show that obesity increases the num-
bers of total and CD11c+ ATMs and that the inﬁltrating ATMs express
high levels of pro-inﬂammatory cytokines such as TNFα. However, con-
sidering the diverse roles of macrophages in classical immunity, studies
that determine the heterogeneity of ATMs and the functions of each
subpopulation in the development of obesity-induced inﬂammation
and insulin resistance are warranted.
3.1.2. Dendritic cells (DCs)
Dendritic cells (DCs) play an important role in the transition of
innate immunity to adaptive immunity by presenting antigens via
MHC II molecules to the T cell receptors (TCRs) of CD4 helper T (Th)Table 3
Cell surface antigens that are commonly used for the ﬂow cytometric analyses of
mouse immune cells.
Antigen name Other name Cells
CD3 T, NKT
CD4 T, DC, Mono
CD8 T, DC
CD11b Mac-1, Itgam Mac, Mono, Neu, NK, T, B
CD11c Itgax DC, Mono, Mac, NK, T, B, Grn
CD14 LPS receptor Mac, Mono, Grn, DC
CD16 FcγRIII Mac, Neu, Mast, NK, NKT, B
CD19 B4 B, Follicular DCs
CD64 FcγRI Mono, Mac, DC, Grn
CD68 Mac, Mono, DC (low)
CD83 DC, T, B
CD115 CSF-1 receptor Mono, Mac
CD205 DEC-205 DC
CD206 Mrc-1, Macrophage mannose
receptor C Type 1
Mac, Mono, DC
CD209 DC-Sign DC
CD301 MGL-1/2 Mac, DC
B220 CD45R B, DC, Mono, T, B, NK
F4/80 EMR-1 Mac, Mono (low), Neu (low)
MHC II DC, B, Mac, mono, T
MK1.1 CD161 NK, NKT
Gr-1 Ly6C/G Neu, Mono, Mac, T, B, DC
Ly6B 7/4 Neu, Mono
Ly6C Mono, Mac, Neu, T, B, DC
Ly6G Neu
It should be noted that this table is only for the general guidance. While some of
markers are highly speciﬁc for the cell types (e.g., CD3 and CD19), some of markers
are less speciﬁc (e.g., CD11c for ATMs). Hence, each investigator should carefully
analyze the expression of markers for the target cells for individual experiment.
Markers with bold fonts represent the cell types that are commonly deﬁned by these
markers. T, T cells; B, B cells; NKT, NKT cells; DC, Dendritic cells (DCs); Mac, macro-
phages; Mono, monocytes; Neu, Neutrophils; NK, NK cells; Grn, granulocytes; low,
low expression levels that can be differentiated from the cells expressing high levels
by ﬂow cytometric analyses.cells [61]. Although macrophages can also present antigens, DCs are
considered to be the primary and professional antigen-presenting
cells (APCs) of the immune system. By contrast, macrophages are con-
sidered to be the primary cells that produce cytokines/chemokines in
chronic inﬂammation. However, DCs can also produce a variety of cyto-
kines that serve to mature and/or activate other immune cells. For
example, the IL-12 produced by DCs induces the differentiation of
naïve T cells into Th1 T cells, while DC-derived IL-15 is important for
the proliferation and activation of CD8 T cells and NK cells. The primary
DC cell-surface marker for ﬂow cytometric analyses is CD11c, although
CD80, CD83 and CD86 are also commonly usedwith other markers [55]
(Tables 2 and 3). DCs are also smaller and less granular than macro-
phages and therefore form a distinctive cluster in FSC/SSC gating in
ﬂow cytometry (Fig. 2A). While DCs are considered to be myeloid
cells, there are also subpopulations of DCs that derive from the lym-
phoid lineage: they can be differentiated from the myeloid lineage-
derived DCs by their expression of CD4 or CD8. However, they do not
express CD3.
Since the primary function of DCs is antigen presentation in adap-
tive immunity and obesity-induced inﬂammation is generally consid-
ered to be due to innate immunity, the role of DCs in obesity-induced
inﬂammation has not yet been extensively studied. However, deple-
tion of CD11c+ cells by using CD11c-DTR (diphtheria toxin receptor)
transgenic mice improves obesity-induced insulin resistance and de-
creases pro-inﬂammatory cytokine expression in AT and muscle [62].
The depletion of CD11c+ cells also decreases hepatic steatosis and
lipid metabolism-related gene expression in the liver. The original
objective of this study was to speciﬁcally target CD11c+ ATMs and
therefore determine the role CD11c+ ATMs play in the development
of obesity-induced inﬂammation and insulin resistance. Since there
are more CD11c+ ATMs than CD11c+ DCs in AT, the effects of
CD11c+-cell deletion on local AT inﬂammation may be largely due
to the deletion of CD11c+ ATMs. However, since CD11c is the classical
marker of DCs and there are more systemic CD11c+ DCs than CD11c+
macrophages in the whole body, this study actually examined the
effects of depleting all CD11c+ cells in the body, including the major-
ity of systemic DCs and the small numbers of CD11c+ ATMs [55].
Hence, this study inadvertently suggests that DCs may actually play
an important role in the regulation of obesity-induced inﬂammation
and insulin resistance.
Two recent studies directly asked what role DCs play in the devel-
opment of obesity-induced insulin resistance. They both showed that
obesity increases DC numbers in AT [63,64]. Bertola et al. also found
that AT contains all three DC subpopulations, namely, myeloid,
CD4+, and CD8+ DCs, and that obesity decreased the frequency of
CD103 DCs [64], which are known to be important in the differentia-
tion of regulator T (Treg) cells in small intestinal lamina propria [65].
Interestingly, the AT DCs isolated from obese animals and humans can
induce the differentiation of Th17 cells (IL-17-expressing T cells) in
vitro [64]. Treg differentiation and Th17-cell differentiation often
counter-balance each other and it has already been shown that the
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yet been identiﬁed in AT from lean or obese animals. Thus, it will be
interesting to see whether CD103 DCs can regulate obesity-induced
inﬂammation in AT by regulating the balance of Treg and Th17 cell
differentiation in vivo. Stefanovic-Racicit et al. also showed that dele-
tion of DCs in Flt3l−/− knockout mice improved obesity-induced insu-
lin resistance along with decreasing the numbers of ATMs and liver
macrophages. Moreover, the reconstitution of DCs in the Flt3l−/−
knockout mice increased the number of ATMs and liver macrophages
[63]. However, the deletion of Flt3l caused signiﬁcant losses in body
weight and adiposity, probably because of increased energy expenditure.
Therefore, it is not clear whether the improvement of obesity-induced
insulin resistance in this model is solely due to the depletion of DCs.
It was shown recently that B cells also participate in the development
of obesity-induced insulin resistance [66,67] (see also Section 3.2.2). This
suggests that adaptive immunity may also contribute to the develop-
ment of obesity-induced inﬂammation. Therefore, it will be interesting
to determine whether DCs play a role in the development of obesity-
induced inﬂammation by promoting adaptive immunity.
3.1.3. Neutrophils
Neutrophils are a member of the granulocytes, which also include
basophils and eosinophils [68–70]. These three granulocyte types can
be differentiated by hematoxylin and eosin (H&E) staining: the neu-
trophils are neutral pink while the basophils and eosinophils are
dark blue and bright red, respectively. Neutrophils play a critical role
in innate immunity, especially in microbial infections. As indicated by
the term “granulocyte”, neutrophils bear large numbers of granules
(intracellular vesicles) that contain anti-microbial reagents, including
lysozyme, neutrophil elastase (NE), myeloperoxidase (MPO), and
defensins. When neutrophils encounter foreign invading pathogens,
they release these anti-microbial reagents by degranulation. They also
remove the foreign pathogens by phagocytosis. Hence, neutrophils
play a primary role in defending the body from infections and are the
ﬁrst cells to migrate into sites of infection. This rapid responsiveness is
aided by the fact that neutrophils are very mobile and fully mature
when they egress from the bone marrow (BM); by contrast, most
other immune cells are naïve when they egress from BM and circulate
in the blood. However, neutrophils can also be matured further in the
local sites so that they produce large amounts of cytokines and
chemokines, including TNF-α, IL-1β, IL-8 and MIP-1α. This allows
them to recruit the second wave of other immune cells, in particular
macrophages. The recruited cells can be further activated by the cyto-
kines that are produced by neutrophils. In ﬂow cytometric analyses,
neutrophils are often deﬁned by their high granularity (high SSC) and
by using the Gr-1 antibody. Since the Gr-1 antibody recognizes both
Ly6C and Ly6G, and Ly6G is expressed only by neutrophils but not by
monocytes, Ly6G antibody is also used for neutrophil-speciﬁc gating
in ﬂow cytometry. Antibodies to CD11b are also used to recognize
activated neutrophils, especially in in vitro studies.
Since the presence of neutrophils at local infected sites is often con-
sidered as evidence of inﬂammation, classical immunologists have fre-
quently asked whether neutrophils can be found in obese AT. This
question was answered by a study that assessed the expression of
MPO in total AT [71] and by a ﬂow cytometric study of AT immune
cells [72]. Both studies showed that obesity increases neutrophil inﬁl-
tration, although the AT neutrophil numbers are much smaller than
the ATM numbers (>30 fold smaller). Both studies also revealed that
neutrophil numbers increase within the ﬁrst week of HFD treatment,
which suggests that like in classical immune responses, neutrophils
may be one of the ﬁrst immune cells to migrate into AT in response to
obesity. However, the MPO expression levels decreased after the ﬁrst
week of HFD treatment [71] whereas the ﬂow cytometric analyses
showed that AT neutrophil numbers were sustained after the ﬁrst
week [72]. This suggests that AT neutrophils may play different roles
during the different stages of obesity. When Talukdar et al. furtherinvestigated the role of NE in the development of obesity-induced insu-
lin resistance, they showed that the inhibition of NE by genetic deletion
or pharmacological inhibition improves obesity-induced insulin resis-
tance along with suppressing inﬂammation in AT and liver [72]. In
particular, this inhibition decreased CD11c+ ATM numbers.
3.1.4. Eosinophils
Eosinophils are important for innate immunity, especially in the
defense against parasite infections; they also play a central role in
the development of asthma and allergy [73,74]. Eosinophils are nota-
ble in that they play roles in Th2 immunity, unlike neutrophils. Hence,
they produce many Th2 cytokines (such as IL-4, IL-10, IL-13 and
TGF-β) that participate in anti-inﬂammatory immune responses, M2
polarization of macrophages, and differentiation of Th2 effector
T cells. In ﬂow cytometric analyses, Siglec-F is commonly used as an
eosinophil-speciﬁc marker.
The studies on IL-4 in obesity suggest that eosinophils participate
in the development of obesity-induced insulin resistance. The sys-
temic deletion of Stat6, which IL-4 utilizes for signaling, increases
insulin resistance, although Stat6−/− knockout mice also weigh less
and are leaner than the wild-type control littermates [75]. By con-
trast, systemic infusion of IL-4, which presumably activates Stat6
(perhaps along with other signaling pathways), improves insulin re-
sistance. However, the IL-4 infusion also decreases body weight and
adiposity [75]. Analyses of IL-4-GFP mice (4get mice) then revealed
that ~90% of the IL-4-producing AT immune cells under normal
chow conditions are eosinophils, although the number of AT eosino-
phils is very low (~20,000/g of fat) [76]. Furthermore, obesity
decreases AT eosinophil numbers. It was then shown further that eo-
sinophil knockout mice generated from ΔdblGATA mice or IL-4/IL-13
double knockout mice had decreased numbers of M2 (alternatively
activated) ATMs. Furthermore, the eosinophil number decreases in
ΔdblGATA mice exacerbate obesity-induced insulin resistance, while
increases in eosinophils due to overexpression of IL-5 or helminth in-
fections improve obesity-induced insulin resistance [76]. However,
body weight and adiposity changes occurred in all of these models:
the ΔdblGATA eosinophil knockout mice had increased body weight
and adiposity compared to the wild-type controls, while mouse
models that increased eosinophil numbers showed decreased body
weight and adiposity. Hence, it is not clear yet whether the
eosinophil-mediated regulation of obesity-induced insulin resistance
and AT inﬂammation (M2 ATM numbers) is due to the direct and pri-
mary effects of eosinophils on insulin resistance or due to secondary
effects of eosinophils on changes in body weight and adiposity. It
should also be noted that eosinophils mainly play a role in Th2 immu-
nity [73] and that the mouse backgrounds of most studies on this
issue are Balb/c mice, which are Th2 biased. By contrast, most studies
on obesity-induced insulin resistance, including diet-induced obesity
models and the ob/ob and db/dbmice, involve C57/B6 mice, which are
Th1-biased. Therefore, it is not yet known whether the different
backgrounds shape the role of eosinophils in the development of
obesity-induced inﬂammation. Nevertheless, the eosinophil studies
suggest a new possibility, namely that induction of Th2 immunity
(and M2 ATMs) can improve obesity-induced insulin resistance,
either directly by immune modulation of AT or indirectly by changing
obesity. The latter effect is often observed when the immune system
is modulated and then subjected to obesity; however, the molecular
mechanisms that underlie changes in body weight and obesity have
not yet been extensively explored.
3.1.5. Mast cells
Mast cells are also myeloid lineage cells and are abundant in the
barriers that are exposed to the environment, such as skin and the
mucosa [77,78]. It is well established that the uncontrolled activation
of mast cells associates strongly with asthma, allergy and anaphylaxis.
However, recent studies suggest that mast cells also may play an
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and bacteria. When mast cells are activated (e.g., by the aggregation
of the IgE receptor Fcε RI), they secrete various arrays of inﬂammato-
ry mediators including histamine, heparin, major basic protein
(MBP), lipid mediators (PGE2 and LTB4), proteases (chymases and
trptases), and pro- and anti-inﬂammatory cytokines (TNFα, IL-1β,
IL-6, TGF-β, IL-4 and IL-10). Hence, mast cells play various functions
in different tissues, especially in terms of activation of other immune
cells. Interestingly, mast cells are often compared to basophils due to
their overlapping phenotypes and functions in immunity. However,
basophils and mast cells differ in their development: in particular,
basophils egress from the BM as mature cells (like neutrophils)
whereas mast cells egress as an immature form and are only fully
activated when they migrate into the local tissue. In addition, they
produce different mediators. In particular, basophils mainly produce
Th2 cytokines (IL-4 and IL-13) while mast cells produce both Th1
and Th2 cytokines. The common technique for detecting mast
cells is immunohistochemistry with toluidine blue staining and/or
immunohistology with antibody against tryptase. In toluidine blue
staining, mast cells stain a red-purple (metachromatic staining)
with a blue background (orthochromatic staining). In terms of genetic
studies of mast cells, KitW-sh/KitW-sh mice have been widely used. They
have a mutation upstream of the c-Kit gene that mainly impairs mast
cell development without inducing too many other abnormalities.
In humans and mouse models, the mast cell numbers in AT are
also increased by obesity [79]. Furthermore, in mast cell-deﬁcient
KitW-sh/KitW-sh mice or mice treated with a mast cell stabilizer
(disodium cromoglycate), obesity-induced insulin resistance is im-
proved. This deletion or stabilization ofmast cells also almost completely
abolishes ATM numbers. However, body weight and adiposity in
these mouse models are also decreased. When KitW-sh/KitW-sh mice are
reconstituted with mast cells, their obesity-induced insulin resistance
worsens. Interestingly, the reconstitution of these mice with mast cells
from Il6 or Ifng knockout mice did not increase insulin resistance,
which suggests that IL-6 and IFN-γ from mast cells play an important
role in the ability of mast cells to regulate metabolism [79]. The authors
of this report proposed that mast cells regulate ATMs, after which
ATMs regulate angiogenesis in obesity. While there is no direct strong
evidence to support this hypothesis, it is interesting because it can
explain the changes in body weight and adiposity that are mediated by
mast cells. Nevertheless, mast cell deletion mainly appears to improve
insulin resistance by changing body weight and adiposity rather than
by directly regulating obesity-induced inﬂammation.
3.2. Lymphocytes
Lymphocytes include T cells, B cells, NK cells and NKT cells, all of
which are synthesized in the BM [46]. T and B cells recognize speciﬁc
antigens with their receptors (TCR for T cells and BCR for B cells) and
therefore play important roles in adaptive immunity. By contrast, NK
and NKT cells are thought to play roles in innate immunity, although
recent studies suggest that they are also important in adaptive
immunity.
3.2.1. T cells
T cells are generated in BM, egress from BM in an immature form,
and are then fully matured in the Thymus [80]. T cells are very hetero-
geneous and are categorized on the basis of their surface expression
markers and/or functions. The ﬁrst categorization of T cells is based
on the TCR subtypes that are expressed on all T cell populations.
Most T cells express αβTCR and are therefore called αβT cells.
However, there is a small population (typically b2% of total T cells)
of T cells that express γδTCRs (γδT cells). γδT cells are present at
high numbers in the gut mucosa and the epidermal compartment of
skin and do not require MHC molecules for their functions (i.e. they
show no MHC-restriction). Although they express CD3, they do notusually express CD4, and their CD8 expression is variable. γδT
cells also produce various anti- and pro-inﬂammatory cytokines,
notably IL-17. However, the role of γδT cells in the development of
obesity-induced inﬂammation and insulin resistance has not yet
been extensively explored, although it will be interesting to examine
their roles in subcutaneous AT due to its close proximity to the skin
intraepithelial area and its lower levels of inﬂammation compared
to epididymal AT.
αβT cells are divided by the CD4 and CD8 surface markers and/or
by their functions (T helper cells, cytotoxic T cells, regulatory T cells
etc.). Most helper cells are CD4 cells and they interact with antigens
presented by MHC II molecules (MHC II-restriction) on APCs. T helper
cells are themselves further divided into Th1, Th2, Th17 and regulato-
ry T (Treg) cells [81]. These CD4 T cell subpopulations are mainly
deﬁned on the basis of intracellular staining for their signature
cytokines: IFNγ for Th1 cells, IL-4 or IL-13 for Th2 cells, IL-17 for
Th17 cells, and IL-10 (and Foxp3) for Treg cells. This staining is
often performed after ex vivo stimulation of the cells with PMA and
anisomycin. However, cell-surface markers speciﬁc for each subpopu-
lation have not yet been fully established. It should also be noted that
these categorizations may be too simpliﬁed. For example, there
are T cell subpopulations that simultaneously express multiple signa-
ture cytokines (e.g., IFNγ and IL17). Furthermore, these immune re-
sponses are dependent on the background of the mice. The C67B/6
background is Th1 biased while the Balb/c or 129 backgrounds are
Th2 biased. The molecular mechanisms underlying this are not fully
understood. Nevertheless, these T cell categorizations are widely used
in the immunology ﬁeld, including in studies of obesity-induced
inﬂammation.
CD8 T cells are often thought to be synonymous with cytotoxic T
cells (CTLs) [82]. However, depending on the experimental condi-
tions, CD4 T cells can also show cytotoxic activity. The primary role
of cytotoxic lymphocytes is to kill infected or non-self cells. To identi-
fy infected/non-self cells, CD8 T cells recognize MHC I-presented
non-self antigens via their antigen-speciﬁc TCRs (MHC I-restriction).
While MHC II molecules are only expressed by APCs, including DCs,
macrophages, neutrophils and B cells, MHC I molecules are ubiqui-
tously expressed by all cells. Hence, when CD8 cells detect foreign
antigens that are presented by MHC I molecules, they recognize
that those cells are infected and kill them by using perforin and
granzymes. In addition, CD8 T cells secrete large amounts of cytokines
(e.g., IFN-γ) that help to induce the death of infected cells. However,
these cytokines can also regulate the development and activation of
other immune cells.
The roles of most of the αβT cell subpopulations, except Th17
cells, in the development of obesity-induced inﬂammation and insu-
lin resistance have been studied. These studies are summarized here.
3.2.1.1. CD4 T cells. Recombination-activating genes (RAGs) play an
important role in the recombination and rearrangement of TCRs in T
cells and immunoglobulins in B cells. Hence, deletion of RAGs will
abolish T cells (including NKT cells) and B cells. Therefore, Rag knock-
out mice are often used for T and B cell studies. When Rag1-/- knock-
out mice are placed on a HFD, they gain weight and adiposity and
become insulin resistant, which suggests that T and B cells may play
a role in obesity-induced insulin resistance [83]. However, these stud-
ies should be interpreted carefully because their effects on insulin
resistance are partnered by effects on obesity.
Obesity also increases total CD3+ T cell numbers and IFNγ+ CD3
or CD3+ CD4+ T cell numbers in AT [83,84]. Furthermore, deletion
of IFNγ in the whole body improves obesity-induced insulin resis-
tance without changing body weight [84]. The deletion of IFNγ also
lowers obesity-induced macrophage inﬁltration and the AT expression
of pro-inﬂammatory cytokines such as TNFα or RANTES. Hence,
IFNγ-expressing Th1 T cells may exacerbate the development of
obesity-induced inﬂammation and insulin resistance. However, these
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Rag1−/− knockout mice lack CD4 Th1 T cells (along with other cells)
and would be expected to show improved obesity-induced insulin
resistance rather than exacerbation [83].
However, Rag1−/− mice also lack Th2 T cells, which may explain
their metabolic proﬁle. Winer et al. showed that the reconstitution
of CD4 T cells in Rag1−/− knockout mice lowered their body weight
and improved insulin resistance [83]. By contrast, reconstitution
with CD4 T cells from Stat6−/− knockout mice (which have impaired
Th2 T-cell development, but have normal Th1 T-cell development)
did not improve insulin resistance. Depletion of CD3 T cells by using
a neutralizing anti-CD3 antibody also improves obesity-induced insu-
lin resistance; a phenotyping switch of the ATMs fromM1 to M2mac-
rophages was observed as well. However, in another study, CD3 T cell
depletion using the same approach with a F(ab′)2 anti-CD3 antibody
only induced a mild improvement in young (but not old) HFD-fed
mice [85]. Nevertheless, these data altogether strongly suggest that
CD4 Th2 T cells play a suppressive role in the development of
obesity-induced insulin resistance by checking ATM inﬂammation. In-
terestingly, Winer et al. also showed that reconstitution of Rag1−/−
knockout mice with CD8 T cells did not improve obesity-induced insulin
resistance [83]. Furthermore, reconstitution of these mice with Foxp3-
CD4 T cells or CD4 T cells from Il10 knockout mice resulted in the same
degree of improvement in obesity-induced insulin resistance as reconsti-
tution with total CD4 T cells [83]. These results directly contradict the
reports that will be described below, which show strongly that CD8
T cells and CD4 Tregs play an important role in the development of
obesity-induced inﬂammation and insulin resistance [86,87].
Signiﬁcantly, all three reports showed consistently that the TCR rep-
ertoires of AT CD4 T cells, CD8 T cells, and CD4 Tregs are very different
from those populations in other tissues (e.g., spleen) [83,86,87]. This
suggests that either the AT T cells are specialized populations or that
there is clonal expansion in AT in response to an unknown antigen.
3.2.1.2. CD4 regulatory T cells (Tregs). Tregs play an important role in
the suppression of inﬂammation [88]. Hence, Treg deletion causes
the spontaneous development of several diseases, at least in mouse
models, including Type 1 Diabetes, rheumatoid arthritis and colitis.
In most cases, Tregs are deﬁned as CD4+, CD25+ and Foxp3+,
although CD8 Tregs have also been shown to exist. Foxp3 is a nuclear
transcription factor that is a key regulator of the development and
activation of Tregs. Since CD25 is often used as an activation marker
for T and B cells, the “real” Treg population can only be determined
by Foxp3 staining. However, since Foxp3 staining requires cell perme-
abilization and intracellular staining of Foxp3, it is not suitable for
many experiments, such as those measuring gene expression proﬁles.
Therefore, many studies have used CD4 and CD25 (IL-2Rα) to identify
Tregs, even though only half or one-third of CD4+ CD25+ cells are
Foxp3+. Recently, Foxp3-GFP knockin mice are often used to identify
and sort Tregs, as they do not require intracellular staining of Foxp3.
Tregs suppress other immune cells by producing IL-10 and TGFβ,
which are classical anti-inﬂammatory cytokines and signature cyto-
kines of Tregs. Interestingly, the frequencies of Tregs and Th17 cells
often show an inverse relationship, as their differentiation processes
are also counterbalanced. However, the in vivo presence of Th17 T
cells in AT under normal chow conditions or a HFD has not yet been
reported.
When Feuerer et al. examined the role of Tregs in the develop-
ment of obesity-induced inﬂammation and insulin resistance, AT
was found to contain a surprisingly high frequency of CD4 Tregs in
normal chow conditions (~40% of CD4 T cells) [87]. Indeed, the
frequency of this cell population in AT is higher than its frequency
in other tissues, including the spleen, lymph node, lung and liver.
Furthermore, the AT Tregs had very different genetic signatures
compared to splenic and LN Tregs. Interestingly, obesity dramatically
decreased Treg frequencies. When Tregs were depleted by usingFoxp3-DTR (diphtheria toxic receptor) transgenic mice, insulin resis-
tance developed spontaneously and the in vivo insulin signaling in
insulin-responsive tissues, including AT, was also impaired. In addi-
tion, thiswas associatedwith increased pro-inﬂammatory gene expres-
sion in AT. By contrast, expansion of Tregs in HFD-fed mice by injecting
the IL-2/anti-IL-2 antibody complex improved obesity-induced insulin
resistance. An in vitro study suggested that the improvement of inﬂam-
mation and insulin resistance is mediated by IL-10 produced by Tregs.
These results suggested strongly that Tregs regulate obesity-induced
insulin resistance by checking AT inﬂammation in obesity [87].
Interestingly, the AT Tregs from obese animals contain high levels
of lipid. Furthermore, genetic analyses of these Tregs and other tissue
Tregs revealed that only AT Tregs strongly express PPARγ and
PPARγ-target genes [89]. Moreover, treatment of HFD-fed mice with
thiazolidinediones (TZDs) increased Treg numbers in AT compared
to those in untreated HFD controls. The deletion of PPARγ in Tregs
by using Foxp3-Cre mice showed that under normal chow conditions,
only the Treg numbers in AT were decreased; the Treg numbers in the
spleen were not affected. Under a HFD, the Treg-speciﬁc PPARγ−/−
knockout mice had the same number of Tregs in AT as the wild-type
control mice and developed the same degree of obesity-induced insulin
resistance. However, when the Treg-speciﬁc PPARγ−/− knockout mice
were treated with TZDs, their Treg numbers in AT did not increase
and obesity-induced insulin resistance did not improve, whereas the
wild-type control mice showed increased AT Treg numbers and im-
proved insulin resistance. Hence, these results together suggest strongly
that TZDs may improve insulin resistance by targeting the AT Tregs.
3.2.1.3. Cytotoxic CD8+ T cells. The primary function of CD8 T cells to
kill infected cells by using perforin and granzyme and by producing
inﬂammatory cytokines. Obesity increases CD8 T cell numbers in AT
and also induces IFNγ and granzyme B expression [83,85,86].
Nishimura et al. then showed that depletion of CD8 T cells improves
obesity-induced insulin resistance; this is associated with a speciﬁc
decrease in CD11c+ ATM numbers, whereas CD11c- ATM numbers
are unchanged [86]. In addition, the depletion of CD8 T cells lowered
the obesity-induced increases in the expression of pro-inﬂammatory
cytokines such as IL-6 and TNFα. Furthermore, reconstitution of
CD8a−/− KO mice fed on a HFD with splenic CD8 T cells exacerbated
obesity-induced insulin resistance; this was associated with increases
in CD11c+ ATM numbers, no changes in CD11c− ATM numbers, and
increased AT IL-6 and TNFα gene expression. Since these data show
strongly that CD8 T cells regulate ATM numbers and that the changes
in AT CD8 T cell numbers precede the increases in ATM numbers in
obesity, Nishimura et al. proposed that AT CD8 T cells induce the re-
cruitment of ATMs in obesity, thereby mediating the development
of insulin resistance. Interestingly, they also showed that in vitro
co-culture of splenic CD8 T cells with AT from HFD mice increased
CD8 T cell proliferation compared to the response to AT from lean
controls. This suggests that in obesity, there may be clonal expansion
of AT CD8 T cells. This result is important as it indicates an important
mechanism by which obesity leads to the expansion of CD8 T cells
(and potentially other T cells) in AT. However, that this obese
AT-induced proliferation of CD8 T cells also occurs in vivo should be
conﬁrmed.
3.2.1.4. Natural killer T (NKT) cell. NKT cells are a very specialized T cell
subpopulation that expresses both CD3 and NK1.1, which is a cell
marker for NK and NKT cells [90]. Hence, NKT cells (CD3+ NK1.1+)
can be differentiated from CD4 and CD8 T cells, which are NK1.1−
(NK1.1− CD3+). It can also be differentiated from NK cells, which
are CD3− (CD3− NK1.1+). In most cases, NKT cells do not recognize
peptide antigens that are presented by MHC I or MHC II molecules.
Instead, they typically recognize lipid antigens that are presented by
CD1d, which is a specialized antigen-presenting molecule that is
expressed by many cell types, including DCs, macrophages, adipocytes
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that are not CD1d-restricted and instead utilize MHC molecules.
α-galactosylceramide (α-GalCer) is commonly used as an artiﬁcial
ligand for NKT-cell activation. NKT cells are categorized into two
major subpopulations based on their TCR sequence variations. The
type I NKT cells (also known as invariant NKT cells, classical NKT cells,
or iNKT) have TCRs with an invariant α chain (Va14-Ja18 in mice and
Va24-Ja18 in humans). The type II NKT cells (also known as variant
NKT cells, non-classical NKT cells, or vNKT cells) have more diverse
TCR sequences. Hence, CD1d−/− knockout mice lack both iNKT and
vNKT cells whereas Jα18−/− knockout mice only lack iNKT cells. NKT
cells produce variety of cytokines, including IL-4, IL-13, IFNγ and
TNFα, and therefore can mediate either Th1 or Th2 responses.
Since NKT cells recognize lipid antigens, it is of particular interest
to determine the role NKT cells play in the development of
obesity-induced insulin resistance. NKT cells are the major compo-
nent of liver T cells (30–50% of T cells) and the deletion of iNKT
cells exacerbates hepatic steatosis. Therefore, early studies in obesity
mainly focused on the effect of NKT cells in the liver. These studies
showed consistently that obesity decreases NKT-cell numbers in the
liver. Recently, CD1d−/− and Jα18−/− knockout mice were used to
examine the roles of NKT cells in obesity more directly. However,
these studies reported very contradictory results: the mice exhibited
improved, exacerbated, or equivalent obesity-induced insulin resis-
tance phenotypes [91–99]. In most cases, the studies used the same
mouse lines and very similar experimental procedures. At this point,
the reason for these signiﬁcant discrepancies is not clear. Another
study using β2-microglobulin (B2M) knockout mice, which lack
NKT cells, revealed that they are not susceptible to obesity-induced
insulin resistance, which suggests that NKT cells may play a role in
the development of obesity-induced insulin resistance [97]. However,
B2M is a component of MHC I, and B2M knockout mice also lack CD8
T cells. The latter study as well as other studies also showed that the
injection of α-GalCer mildly worsened obesity-induced insulin resis-
tance. However, it is also well-known that α-GalCer-activated NKT
cells cause a cytokine storm that artiﬁcially induces the secondary
activation of a variety of immune cells, including CD4 and CD8 T
cells and NK cells [100–105]. Hence, the role of NKT cells in the devel-
opment of obesity-induced inﬂammation and insulin resistance is not
fully established yet and must be investigated further.
3.2.2. B cells
B cells are another arm of the adaptive immune system along with
T cells [106,107]. Although the name “B cells” derives from the notion
that B cells develop fully in the Bone marrow (unlike the T cells,
which develop in the Thymus), B cells egress from the BM as an im-
mature form that has fully developed BCRs and expresses IgM. The
B cells then migrate into the secondary lymphoid organs such as the
lymph nodes or spleen, where they mature fully and differentiate
into plasma cells that produce antibodies, including various IgG
subtypes. The Rag−/− and μMT mouse models are often used to ana-
lyze B cell functions. Rag−/− mice lack both T and B cells whereas
μMT mice do not have IgM and therefore lack mature B cells without
any primary defects in other immune cells. The typical markers for
ﬂow cytometric analysis include CD19 and CD45R (B220). The
major function of B cells is to produce antibodies that are speciﬁc
for foreign antigens in humoral immunity. To fully activate B cells,
they must interact with Th2 cells. When BCRs recognize their free
antigens (B cells do not require MHC presentation for the recognition
of antigens, unlike T cells), the antigens are engulfed, digested, and
presented on MHC II molecules. Primed Th2 cells (activated T cells
that have a speciﬁc TCR for the matching antigen) can interact via
their TCRs with the MHC II on B cells, after which the Th2 cells
produce cytokines that cause the full development of B cells and
maximize their production of antibody. This process is called
“T cell-dependent activation” and most B cell activation occursthrough this process (B cells can be activated via T cell-independent
activation but only at low frequencies). However, B cells can also
produce cytokines in various functions. Recently, it was shown that
B cells can act as suppressors. Since these suppressive B cells are
similar to Tregs in terms of their suppressor role in inﬂammation
and their secretion of the anti-inﬂammatory cytokine IL-10, they are
also known as regulatory B cells (Bregs).
Recent studies showed that obesity increases the B cell population in
AT, especially IgG-producing mature B cells [66,67]. Moreover, the μMT
mice on a HFD show improved obesity-induced insulin resistance, al-
though their epididymal fat weight is decreased; interestingly, changes
in subcutaneous fat weight are not observed [66,67]. The depletion of B
cells by a neutralizing antibody also improves obesity-induced insulin
resistance. The μMT mice on a HFD also show decreases in CD11c+
ATM numbers and CD8 T cell activation along with increased AT Treg
numbers and M2 ATM signature gene expression in AT. This is accom-
panied by decreases in pro-inﬂammatory cytokine levels in AT as well
[66,67]. Interestingly, IL-17 gene expression in AT is also decreased,
which suggests that there may be a link between B cells and Th17 cells.
Winer et al. examined the adaptive immunity role of B cells in the
development of obesity-induced insulin resistance further [66]. They
reconstituted B cells from mice fed normal chow or a HFD into
HFD-fed μMT mice and found that only the B cells from HFD-fed
donor mice worsened insulin resistance; the B cells from normal
chow-fed donor mice did not change the insulin resistance pheno-
types. They tested this further by using puriﬁed Ig from mice fed
normal chow or a HFD. Again, HFD-fed μMT mice injected with IgG
puriﬁed from HFD-fed mice showed increased obesity-induced insu-
lin resistance. The IgG from normal chow-fed mice had no effect.
However, when Rag1−/− knockout mice were reconstituted with
B cells, obesity-induced insulin resistance did not increase. This
suggests that B cells require T cells to induce the development
of obesity-induced insulin resistance. This notion was tested by
reconstituting μMT mice with B cells from MHC I or II knockout
mice: neither mutant B cell population promoted the development
of insulin resistance. These results strongly suggest that B cells must
interact with CD4 T cells and/or CD8 T cells in obesity before insulin
resistance can develop fully. On the other hand, injection of μMT
mice with F(ab′)2 fragments of IgG puriﬁed from HFD-fed mice did
not exacerbate obesity-induced insulin resistance. This suggests that
the Fc receptor may be involved in the insulin resistance-inducing
actions of B cells. Finally, Winer et al. screened for antigens by using
antibodies isolated from insulin-sensitive and -resistant human sub-
jects. Potential candidates that were recognized by these antibodies
from each group were identiﬁed. Interestingly, the antibodies from
the two groups recognized almost equal numbers of candidate
proteins.
These studies altogether show that B cells play a role in the devel-
opment of obesity-induced inﬂammation and insulin resistance.
Furthermore, Winer et al. showed that adaptive immunity of B cells
may also play a signiﬁcant role in these processes [66]. Since this
study potentially changes the paradigm of obesity-induced inﬂamma-
tion, which was long thought to be mediated by innate immunity,
studies that verify the observations of Winer et al. are needed.
4. Molecular players in obesity-induced inﬂammation
Many molecules that mediate the development of obesity-induced
inﬂammation in total AT and AT immune cell compartments have
been identiﬁed. To identify these molecules, the majority of studies
used genetic mouse models including total body knockout mice, bone
marrow transplantation (BMT) of total body knockout mice, and
myeloid-speciﬁc knockout mice using LysM-Cre mice. By targeting me-
diators in the development of obesity-induced inﬂammation and insulin
resistance, these studies have elucidated important molecular mecha-
nisms that underlie the development of obesity-induced inﬂammation.
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membered when interpreting their results. First, all three mouse model
systems involve the systemic modulation of the target gene(s) rather
thanmodulating the gene in theAT immune cell compartment only. Ob-
viously, total body knockout mice delete target genes in all tissues/cells,
and BMT replaces all immune cells in all tissues. While myeloid-speciﬁc
gene deletions by using LysM-Cremice yield themost speciﬁcmodels, all
myeloid cells (includingDCs,macrophages, neutrophils and eosinophils)
are targeted by these deletions.
Another point that should be considered is that many immunolog-
ical modulations affect body weight and adiposity. In most cases,
body weight and adiposity decreases are associated with improve-
ments in obesity-induced insulin resistance, and vice versa. Hence,
the metabolic phenotypes in those studies should be interpreted
carefully. Table 4 summarizes the effect of gene deletion on metabolic
phenotypes and body weight and adiposity. Although it may be very
important to determine how these immune modulations regulate
body weight and adiposity, this issue has not yet been studied exten-
sively. Since there are many excellent reviews that overview the roles
of various molecular players in the development of obesity-induced
inﬂammation and insulin resistance, we will only discuss selected
pathways in this review.
4.1. The IKKβ/NFκB pathway
NFκB plays a critical role in regulating inﬂammation [108,109]. In
the basal (resting) state, NFκB is sequestered in the cytoplasm by its
binding to IκBα; this binding masks its nuclear localization sequence
(NLS).When cells are stimulatedwith various stimuli, including growth
factors, cytokines and foreign pathogens or molecules such as LPS, the
IKK enzyme complex is activated and IKKβ phosphorylates Ser32 and
36 of IκBα. This phosphorylation induces the proteasome-dependent
degradation of IκBα, which exposes the NLS of NFκB and causes NFκB
to translocate into the nucleus, where it initiates the gene expression
of various inﬂammatory mediators. Many NFκB target genes, including
TNFα, IL-6 and MCP-1, are also implicated in the development of
obesity-induced insulin resistance.
In obese animals, NFκB activity is increased [31]. Furthermore,
when the IKKβ/NFκB pathway in animal models is inhibited by phar-
macological inhibitors of IKKβ (a high dose of salicylates and aspirin)
or by genetic deletion of IKKβ, the obesity-induced insulin resistance
improves [30,31]. More importantly, treatment of insulin-resistant or
T2D patients with aspirin or salsalate (a dimer of salicylates) improves
their glycemic control along with inhibiting NFκB activity in their
PBMCs [32–35]. The deletion of IKKβ in myeloid cells by using LysM-Cre
mice also protects these mice from developing obesity-induced insulin
resistance [110]. These results strongly suggest that the suppression of
IKKβ/NFκB-dependent inﬂammation improves insulin resistance and
T2D in animal models as well as in humans.
The question is then, “How does obesity activate the IKKβ/NFκB
pathway?” Since TLRs are considered to be major upstreammolecules
in the activation of the IKKβ/NFκB pathway in many immune systems
[111], the role of the TLR signaling pathway in the development of
obesity-induced inﬂammation and insulin resistance has been exam-
ined. While LPS is the best-known ligand for TLR4, FFA can also acti-
vate TLR4 [112,113]. Furthermore, deletion of TLR4 in the whole
body protects mice from the development of lipid- and diet-induced
insulin resistance [112]. Interestingly, female tlr4−/− mice gained
more weight (and adiposity) while exhibiting improved insulin resis-
tance compared to the wild type controls [112]. Moreover, C3H/HeJ
mice, which have a spontaneous loss-of-function mutation in TLR4,
are also protected from diet-induced insulin resistance; however, in
this case, the mutant mice also have decreased weight and adiposity
[114]. More recent studies show that ceramide-mediated insulin
resistance is also mediated by TLR4 [115]. Since these studies used
total body knockout or mutant mice, it was not clear whether it wasthe TLR4 on hematopoietic cells that promoted the development of
insulin resistance. This question was tested by transplanting BM
from total body TLR4 knockout mice into irradiated wild-type mice:
the deletion of TLR4 in the hematopoietic compartment protected
the mice from diet-induced insulin resistance [116]. However, this
study did not examine the role of TLR4 in the peripheral compart-
ment by reconstituting irradiated tlr4−/− knockout mice with WT
BM. Curiously, TLR4 deletion does not improve insulin resistance in
all studies. A recent report showed that total body TLR4 knockout or
deletion of TLR4 in the hematopoietic or non-hematopoietic compart-
ments by BMT did not improve diet-induced insulin resistance; in-
deed, it actually exacerbated the insulin resistance somewhat [117].
The latter ﬁndings are supported by results from MyD88 knockout
mice. MyD88 is a universal adaptor molecule for the TLR signaling
pathway and all TLRs require MyD88 to activate the IKKβ/NFκB path-
way. Hence, deletion of MyD88 effectively inhibits all TLR signaling.
The MyD88−/− knockout mice exhibited exacerbated diet-induced
insulin resistance without changes in body weight or adiposity
[118]. Hence, the discrepancies between the latter two studies and
the other studies on TLRs mean that it is not yet clear whether
obesity-induced NFκB-dependent inﬂammation is mediated by the
TLR signaling pathway.
4.2. Jun N-terminal kinases (JNKs)
The Jun N-terminal kinase/stress-activated protein kinases (JNK/
SAPKs) belong to the MAP (mitogen-activated protein) kinase family
and are involved in many different stress pathways [41,119]. In the
insulin resistance ﬁeld, JNK is known to play a key role in the ER stress
that regulates the development of obesity-induced insulin resistance.
This role relates in part to its phosphorylation of IRS-1 on the Ser307
and 310 (mouse sequence) residues, which inhibits this molecule
[120]. Hence, the deletion of JNKs or its scaffolding protein JIP im-
proves obesity-induced insulin resistance [121,122]. Since JNK in the
ER pathway appears to directly inhibit the insulin signaling pathway,
it directly affects insulin-responsive cells. However, it is debatable
whether JNK in hematopoietic cells participates in the development
of obesity-induced insulin resistance, and if it does, whether it is sole-
ly responsible for this pathogenesis. When Solinas et al. used the BMT
technique with Jnk1−/− knockout out mice, they showed that dele-
tion of Jnk1 in the peripheral (non-hematopoietic) compartment im-
proved diet-induced insulin resistance, although the body weight and
adiposity were also decreased [123]. The deletion of Jnk1 in the hema-
topoietic compartment also improved diet-induced insulin resistance
but without changing the body weight and adiposity [123]. Therefore,
this report suggests that Jnk1 in the hematopoietic compartment
(presumably in myeloid cells) plays a critical role in the development
of obesity-induced insulin resistance. However, when Vallerie et al.
used the same mouse model and a similar BMT technique, they
found that obesity-induced insulin resistance only improved when
Jnk1 was deleted in the peripheral compartment; deletion of Jnk1 in
the hematopoietic compartment had no effect on insulin resistance,
although it did lower the expression of pro-inﬂammatory genes in
AT [124]. Furthermore, the myeloid cell-speciﬁc deletion of Jnk1 did
not induce any changes in metabolic phenotypes either, whereas
adipocyte-speciﬁc deletion of Jnk1 improved obesity-induced insulin
resistance [125]. Hence, the latter two studies support the role of
Jnk1 in the peripheral tissues, especially in adipocytes, but not in my-
eloid cells. Although the discrepancies in these studies are not yet
fully understood, a recent study suggests that Jnk2 in myeloid cells
may play a bigger role in the development of obesity-induced insulin
resistance when Jnk1 is deleted [126]. Total body Jnk2−/− knockout
mice do not affect obesity-induced insulin resistance [121]. However,
when both Jnk1 and Jnk2 are deleted in myeloid cells by using
LysM-Cre mice, the mutant mice exhibit improved insulin resistance
along with suppression of inﬂammation, including decreases in the
Table 4
Molecular players that participate in the development of obesity-induced inﬂammation and insulin resistance.
Gene Targeting Method Insulin Resistance Body Weight Adiposity ATM Reference
Number M1 M2
IKK-β/NFκB signaling pathway
IKK-β T KO ↓ ↔ ↔ ND ND ND [31]
Δmye ↓ ↓ ND ND ND ND [110]
TLR2 T KO ↑ ↑ ↑ ND ND ND [149]
TLR4 T KO ↓ ↓ ↓ ↓ ND ND [114]
T KO ↔(↓) ↓ ↓ ↔ ↔ ↑ [117]
BMT(H):T KO ↓ ↔ ↔ ↓ ND ND [116]
BMT(H):T KO ↔ ↔ ↔ ↔ ND ↑ [117]
BMT(P):T KO ↔ ↔ ↔ ND ND ↔ [117]
MyD88 T KO ↑ ↔ ↔ ND ND ND [118]
JNKs
Jnk1 T KO ↓ ↓ ↓ ND ND ND [121]
Tg:aP2 ↓ ↔ ↔ ND ND ND [150]
BMT(H):T KO ↓ ↔ ↔ ND ND ND [123]
BMT(H):T KO ↔ ↔ ↔ ↔ ND ND [124]
BMT(P):T KO ↓ ↓ ↓ ND ND ND [123]
BMT(P):T KO ↓ ↔ ↔ ↔ ND ND [124]
Δmye ↔ ↔ ↔ ND ND ND [125]
JNK2 T KO ↔ ↔ ND ND ND ND [121]
Jnk1/Jnk2 Δmye ↓ ↔ ↔ ↓ ↓ ↓ [126]
Inﬂammasome
Nlrp3 T KO ↓ ↔ ↓ ND ↓ ↔ [131]
T KO ↓ ↔ ↔ ND ND ND [130]
T KO ↓ ↓ ND ND ND [132]
ASC T KO ↓ ↓ ↓ ↔ ND ND [130]
BMT(H):T KO ↓ ND ND ND ND ND [130]
ASC T KO ↓ ↓ ↓ ↔ ND ND [132]
Casp1 T KO ↓ ↓ ↓ ↓ ND ND [132]
Pycad T KO ↓ ND ND ND ND ND [130]
BMT(H):T KO ↓ ND ND ND ND ND [130]
IL-1β T KO ↓ ND ND ND ND ND [130]
Cytokine/chemoattractants
TNF-α I (Zucker rat) ↓ ↔ ↓ ND ND ND [13,14]
T KO ↓ ↔ ↓ ND ND ND [15,16]
BMT(H):T KO ↓ ↔ ND ND ND ND [17]
TNFαR T KO ↓ ↔ ↓ ND ND ND [14]
IFN-γ T KO ↓ ↔ ↔ ↓ ↓ ND [84]
IL-6 T KO ↑ ↑ ↑ ND ND ND [142]
Il-15 T KO ↑ ↑ ND ND ND [151]
IL-4 I ↓ ↓ ↓ ND ND ND [152]
IL-4/IL-13 T KO ND ND ND ND ND ↓ [76]
IL-1R1 T KO ↓ ↔ ↑ ↔ ND ND [153]
IL-10 Tg ND ND ND ND ↔ ↑ [143]
Inj ↓ ND ↓ ND ND ND [141]
BMT(H):T KO ↔ ↔ ↔ ↔ ND ND [144]
Osteopontin T KO ↓ ↔ ↔ ↓ ND ND [155]
MCP-1 T KO ↓ ↔ ↓ ↓ ND ND [50]
Tg:aP2 ↑ ↔ ↔ ↑ ↑ ND [50,51]
CCR2 T KO ↓ ↓ ↓ ↓ ND ND [156]
CX3CR1 T KO ↔ ↔ ↔ ↔ ↔ ↔ [154]
CXCL5 I ↓ ↔ ND ND ND ND [157]
CXCR2 T KO ↓ ↔ ND ND ND ND [157]
PPARs
PPAR-γ Δmye (Balb/c)
Δmye (C57BL/6)
↑
↔
↑
↔
↑
↔
↓
ND
ND ↓ [147]
[148]
PPAR-δ Δmye ↑ ↑ ↓ ↑ ↑ ↓ [158]
Others
AIM KO:Het ↓ ↑ ↑ ND ↑ ↔ [159]
RP105/MD-1 complex KO:Het ↓ ↓ ↓ ↓ ↓ ↑ [160]
MGL1 KO:Het ↓ ↓ ↓ ND ↓ ND [161]
CD36 BMT(H):T KO ↔ ↔ ↔ ND ↓ ↑ [162]
BLT-1 T KO ↓ ↔ ↑ ↓ ↓ ↑ [163]
SOCS1 Δmye ↑ ↔ ↔ ND ↑ ND [164]
IR Δmye ↓ ↔ ↔ ↓ ND ND [165]
ABCA1 Δmye ↑ ND ND ↑ ND ND [166]
Sorbs1 T KO ↓ ↔ ↔ ↓ ND ND [167]
FABP4/FABP5 BMT(H):T KO ↓ ↔ ↔ ↔ ND ND [168]
KLF4 Δmye ↑ ↑ ↑ ↑ ↑ ↓ [169]
α4 integrin T KO ↓ ↔ ND ↓ ND ND [170]
GPR120 T KO ↑ ↔ ND ↔ ↔ ↔ [171]
T KO, Total body knockout; Δmye, Myeloid-speciﬁc knockout mice generated by using LysM-Cre mice; Tg:aP2, Adipocyte-speciﬁc transgenic mice generated by using aP2 promoter;
BMT(H), Deletion of target genes in the hematopoietic compartment by bone marrow transplantation (Donor: T KO or transgenic mice, Recipients: wild type controls); BMT(P),
Deletion of target genes in the parenchymal (non-hematopoietic) compartment by bone marrow transplantation (Donors: wild type controls, Recipients: T KO or transgenic
mice); Inj, Injection with target molecule; I, inhibitor; ND, No determine.
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pression in AT [126]. Body weight and adiposity were not affected
in the latter mice.
4.3. Inﬂammasome pathway
The inﬂammasome is an intracellularmultimeric complex that plays
an important role in innate immunity [127]. It is often found inmyeloid
cells and the complex includesNRLPs, NALPs, ASC, Pycard and caspase 1.
The main function of the inﬂammasome is to induce the maturation of
IL-1β and IL-18 and therefore to produce these cytokines in response
to danger signals. Hence, the inﬂammasome is only fully activated
when two signaling events occur: increased production of pro-IL-1β
and pro-IL-18 through gene transcription (mainly induced via NFκB
activation by TLRs) and activation of the inﬂammasome so that it
cleaves pro-IL-1β and IL-18 via its caspase-1 (mainly induced by
DAMPs or PAMPs) [128]. Interestingly, cholesterol crystals, which may
mediate atherosclerosis, activate the inﬂammasome [129].
In vitro studies show that FFA or ceramide can activate the
inﬂammasome in BMDMs only when the cells are stimulated with
LPS [130,131]. In addition, Wen et al. found that FFA-induced
inﬂammasome activation requires ROS production and is partially
suppressed by the activation of AMP kinase [130]. Interestingly,
Wen et al. found that FFA treatment (plus LPS) impairs autophagy
and that activation of AMP kinase reverses this. Therefore, the authors
proposed that FFA treatment of macrophages inhibits AMP kinase and
autophagy; this in turn increases ROS production by mitochondrial
damage, which facilitates the FFA/LPS-induced activation of the
inﬂammasome [130]. Although this is a very interesting hypothesis,
it will have to be tested in vivo. Supporting the role of the
inﬂammasome in obesity-induced insulin resistance, three studies
showed that deletion of inﬂammasome components, including
NLRP3, Pycard, caspase 1, or ASC, improved obesity-induced insulin
resistance while suppressing inﬂammation (such as decreasing the
pro-inﬂammatory gene expression in AT and the polarization of M1
ATMs) [130–132]. Furthermore, BMT of Pycard−/− mice show that it
is the inﬂammasome in the hematopoietic compartment, not the
inﬂammasome in stromal compartments, that plays this role in
obesity-induced insulin resistance [130]. However, the details of
these three studies differ, especially in terms of the effect of
inﬂammasome component deletion on body weight and adiposity.
These discrepancies are summarized in Table 4. Hence, it is not fully
clear at this moment whether the inﬂammasome pathway in obesity
regulates obesity-induced inﬂammation and insulin resistance direct-
ly or whether it acts by more indirect mechanisms that are secondary
to changes in body weight and adiposity.
The two cytokines that are regulated by the inﬂammasome are
IL-1β and IL-18. Although the role of IL-18 in the development of
obesity-induced inﬂammation and insulin resistance has not been
studied extensively, the role of IL-1β was recently the focus of
research because of its clinical implications. Treatment of cells or
obese animals with IL-1β induces insulin resistance by inhibiting
the insulin signaling pathway [133,134]. Furthermore, treatment of
obese animals with a neutralizing antibody against IL-1β improves
insulin resistance, although this is thought to be mainly mediated
by the improvement of β-cell functions [135]. These observations
quickly led to a small clinical trial with Anakinra, an IL-1R antagonist:
the antagonist improved the glycemic control in T2D by improving
β-cell functions [136]. Anakinra treatment also lowered the levels of
systemic inﬂammation markers. These studies suggest strongly that
inhibiting IL-1β function, and potentially inﬂammasome activity,
improves insulin resistance and T2D in humans. However, the more
recent CANTOS clinical study of Canakinumab, a humanized monoclo-
nal antibody against IL-1β, showed that IL-1β blocking does not
improve the glycemic control in T2D, although the treatment did
lower inﬂammation [137]. The main difference between the twoclinical trials is that Anakinra targets both IL-1α and IL-1β, while
Canakinumab speciﬁcally neutralizes IL-1β alone. Hence, although the
inﬂammasome and its target cytokines, IL-1β and IL-18, are important
mediators in innate immunity and may also play a role in the develop-
ment of obesity-induced inﬂammation and insulin resistance, more
clinical and preclinical studies are needed to determine the importance
of thesemolecules in the development of obesity-induced insulin resis-
tance and T2D.
4.4. Cytokines
At the cellular level, obesity-induced insulin resistance is caused by
the impairment of the insulin signaling pathway in insulin-responsive
cells (i.e., adipocytes, hepatocytes, myocytes and β-cells). By contrast,
obesity-induced inﬂammation is thought to mainly occur in the
tissue-inﬁltrating immune cells. Therefore, the obesity-inﬂamed im-
mune cells must cross-talk or produce mediators to induce the insulin
resistance in insulin-responsive cells. The main suspects in this interac-
tion are the cytokines that are produced by the obesity-inﬂamed
immune cells. However, the IKKβ/NFκB, JNK and inﬂammasome path-
ways in immune cells can all promote the production of pro- and
anti-inﬂammatory cytokines. In addition, the cytokines produced by
obesity-inﬂamed immune cells also regulate the recruitment, develop-
ment and activation of other tissue-resident immune cells, thus initiat-
ing the secondary wave of cytokine production. Hence, it is difﬁcult to
determine which cytokines directly induce the impairment of insulin
signaling. However, by using genetically modiﬁed mouse models in
conjunction with in vitro studies, many cytokines have been tested for
their roles in the development of obesity-induced inﬂammation and
insulin resistance.
TNFα is a classical pro-inﬂammatory cytokines and its role in insulin
signaling has been studied extensively. Indeed, TNFαwas studied even
before the notion of obesity-induced inﬂammation arose. The early in
vitro studies clearly show that TNFα inhibits insulin signaling by reduc-
ing the levels of insulin signaling components [11,12]. In addition, TNFα
can induce the inhibitory phosphorylation of IRSs, thereby blocking in-
sulin signaling [138]. Many in vivomousemodels also clearly show that
inhibition of TNFα function improves obesity-induced inﬂammation
[13–17]. However, since most of these studies were performed before
the role of ATMs in obesity was established, they did not showwhether
inhibition of TNFα function also changes AT inﬂammation or ATM phe-
notypes. Moreover, clinical trials of an anti-TNFα antibody showed that
it did not improve glycemic control in T2D [139,140], although the same
treatment does improve rheumatoid arthritis.
IL-6 is another classical pro-inﬂammatory cytokine that is a risk
factor for the development of T2D in human [25]. However, mouse
model studies have yielded contradictory results regarding the role
of IL-6 in the development of insulin resistance. Acute IL-6 infusion
of mice induces spontaneous insulin resistance in the absence of obe-
sity [141]. However, mice in which IL-6 is deleted develop late-onset
obesity and insulin resistance [142].
On the other hand, IL-10 is a classical anti-inﬂammatory cytokine.
It is expressed by Tregs at high levels but is also expressed by macro-
phages and other cells. Since IL-10 is anti-inﬂammatory, it is thought
to counter pro-inﬂammatory cytokine functions and therefore pro-
mote the improvement of obesity-induced insulin resistance. Indeed,
overexpression of IL-10 increased M2 ATM numbers [143], and
co-infusion of IL-10 and IL-6 reverses IL-6-mediated insulin resistance
[141]. The Treg studies also support this [87,89]. However, the hema-
topoietic deletion of IL-10 by BMT from Il10−/− knockout mice into
wild-type mice did not change the diet-induced insulin resistance
or inﬂammation [144]. This raises doubts over the role IL-10 plays
in these pathogeneses.
As indicated by these selected examples of in vivo cytokine studies,
cytokines do not follow the anti-inﬂammation vs. pro-inﬂammation
paradigm very well. For example, pro-inﬂammatory cytokines
459B.-C. Lee, J. Lee / Biochimica et Biophysica Acta 1842 (2014) 446–462(e.g., IL-6) can improve insulin resistance [142]. This discordance
between the inﬂammatory functions of cytokines and their meta-
bolic functions may be due to the temporal and local regulation of
inﬂammation. For example, while certain cytokines are needed to
initiate obesity-induced inﬂammation and insulin resistance dur-
ing the early phase of obesity development, they may not be
required in the later phases of obesity. Another possibility is that
it may require several cytokines to coordinately regulate the devel-
opment of disease: a single cytokine is not sufﬁcient for mediating
the complex obesity-induced inﬂammation and insulin resistance.
5. Limitations and future studies
There has been great progress in terms of our understanding of how
obesity-induced inﬂammation is regulated and howmodulations of this
pathway can regulate the development of obesity-induced insulin resis-
tance. However, there are several limitations that we may need to
consider. First, there are many contradictory reports and it is not clear
yet what causes these discrepancies (a good example of this is the liter-
ature on NKT cells). However, it should be also noted that the ﬁeld of
obesity-induced inﬂammation is relatively new and that many of the
studies have been done only limited time. Hence, as the ﬁeld grows
and these conﬂicted results are further tested, we may be able to ﬁnd
causes for these discrepancies. One intriguing idea for this is that the
immunophenotypes observed in different labs may vary because of
microbiome differences. In the immunology ﬁeld, the possibility that
the microbiome can regulate systemic immunity is gaining more sup-
port [145]. It is also clear that the animals in different institutes have
very different microbiomes. Furthermore, the relationship between
microbiome and obesity is also well established [146]. However, how
the microbiome regulates obesity-induced insulin resistance (without
changing obesity) via gut immunity (inﬂammation) has not been exam-
ined extensively. This is a very exciting and important area per se. In any
case, it will be interesting to determine whether diverse microbiomes
may be responsible for the different results of different labs.
Another limitation is the tissue speciﬁcity of immune modula-
tions. Although this review focused on the cellular and molecular
players in AT inﬂammation, most of the studies described here actu-
ally examined the systemic roles of these players. Probably the only
two examples of AT-speciﬁc mouse models are the AT-speciﬁc
MCP-1 transgenic mice [50,51] and the Treg-speciﬁc PPARγ knockout
mice [89]. With the technology that is currently available, it may not
be possible to speciﬁcally target AT. Thus, when interpreting the
studies described here, the effects of immune modulation on systemic
inﬂammation should also be considered.
However, probably the biggest limitation of the current studies is
that most of them are in mouse models. The immune systems of mice
and humans are obviously very different. For example, while neutro-
phils are the most abundant circulating cell type (~two-thirds)
followed by lymphocytes (~one-third) in humans, the order is
reversed in mice: lymphocytes are the most abundant cell type in
the circulation (~two-thirds), followed by neutrophils (~one-third).
Furthermore, the backgrounds of experimental mouse model systems
also regulate immune responses. For example, Balb/c is more biased
to Th-2, while C57/B6, the most commonly used mouse model in obe-
sity, is more Th1-biased. This explains why PPARγ deletion in myeloid
cells in the Balb/c background improved obesity-induced insulin re-
sistance and suppressed inﬂammation [147] when the samemutation
on the C57/B6 background did not improve either obesity-induced
insulin resistance or inﬂammation [148]. It is not clear whether this
is an isolated case that is speciﬁcally limited to PPARγ or reﬂects a
more universal phenomenon. Hence a systematic study that com-
pares these two mouse backgrounds in terms of the development of
obesity-induced inﬂammation and insulin resistance may be needed.
However, humans do not generally display this skewing towards a
Th1 or Th2 background phenotype. Nevertheless, it should be alsonoted that many of the immunological ﬁndings from mouse studies
have been conﬁrmed by human studies. The best example is that
like obese animal models, obese human subjects have more ATMs
than lean subjects. Furthermore, the salicylate-induced improvement
of glycemic control in humans was accurately predicted by preclinical
studies, and the outcomes are fairly comparable in many phenotypes.
However, the biggest limitation, and also the most challenging task in
obesity-induced inﬂammation research, is how to translate the
preclinical study ﬁndings into clinical studies that examine the effect
of inﬂammation-regulating treatments on T2D in humans.
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